Earnings call transcript: M&A Center Q4 2025 shows strong recovery, stock dips

Nihon M&A Center reported FY2025 revenue of JPY 50.25 billion (+14% YoY) and ordinary profit of JPY 19.15 billion (+13.2%), signaling a solid recovery from prior accounting issues. The company guided FY2026 to JPY 52.8 billion in sales and JPY 19.3 billion in ordinary profit, while reiterating a JPY 29 per share dividend and a long-term Vision 300 target of JPY 30 billion in ordinary profit by FY2032. Shares nonetheless fell 5.14% to JPY 654.5 as investors appeared focused on rising costs, headcount turnover, and margin pressure.

Analysis

The market is not debating whether the business is healed; it is debating whether the next leg of growth is self-funding. The real issue is that management is choosing to spend the recovery dividend on people, brand, and process quality right as the operating model is trying to re-accelerate, which means near-term margins may stay capped even if topline stays healthy. That creates a classic second-order setup: quality improvements can support longer-duration franchise value, but only if they translate into higher conversion rates faster than headcount attrition erodes capacity.

The key hidden variable is pipeline quality versus throughput. A smaller intake of lower-quality mandates can look like a demand problem in the numbers, but if the active pipeline is rising and the firm is intentionally filtering out lower-conviction deals, the near-term denominator is misleading. The bigger risk is that the organization is still dependent on a narrow set of senior leaders for recruiting and commercial relationship glue; that is a brittle scaling model and a governance issue, not just an HR issue.

This is also a relative-value story inside Japanese financial services: the company is trying to move from a referral-driven intermediary to a platform with adjacent monetization in PMI, listed-company advisory, and fund economics. That broadens the optionality, but it also raises execution dispersion, because each new revenue line has different operating leverage and customer acquisition mechanics. If the market keeps treating this as a simple recovery story, it may be underestimating the medium-term mix shift; if it starts to price the growth plan fully, the stock needs evidence of retention improvement and deal conversion, not just aspirational targets.

Contrarian view: the selloff is likely less about the reported numbers and more about fear that the best employees are already being asked to do too much in a business that still relies on trust-based distribution. If management can show consultant headcount stabilization over the next two quarters and no deterioration in close rates, the multiple can rerate quickly; if not, the stock becomes a low-trust, high-effort growth trap.

Key Decisions for Investors

• Buy JPN-listed 2127 on weakness over the next 1-2 weeks, but only on evidence the post-earnings drawdown is being absorbed; target a 10-15% rebound if the market refocuses on pipeline expansion and guidance conservatism, with a 5-7% stop if close-rate commentary deteriorates.
• Use a pairs trade: long 2127 / short a lower-quality Japanese services name with weaker visibility and more leveraged growth; this isolates the thesis that trusted distribution and recurring referral economics deserve a premium even if near-term margins stay under pressure.
• For event-driven traders, buy 1-2 quarter call spreads on 2127 rather than outright equity if available; the setup favors a delayed rerating as retention and consultant net-add metrics improve, with better risk/reward than chasing the initial post-print gap.
• If consultant headcount or turnover worsens next quarter, fade the rally and cut exposure immediately; the market will punish any sign that the growth plan is becoming more expensive to sustain than modeled.